Clinical Trials · NCT01469338
Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- University of Southern California
- Enrollment
- 9
- Start date
- Jul 2012
- Locations
- 1 site, United States
- Primary endpoint
- Development of Grade 2 plus diarrhea